OncoMatch/Clinical Trials/NCT04467723
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Is NCT04467723 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Atezolizumab for nsclc stage iv.
Treatment: Atezolizumab — The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR actionable mutation
de novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1)
Excluded: ALK actionable mutation
de novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1)
Excluded: ROS1 actionable mutation
de novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1)
Allowed: PD-L1 (CD274) TPS < 1%
PDL1 TPS score less than 1% or unknown: first-line must be PD1/PDL1 inhibitor in combination with chemotherapy
Disease stage
Required: Stage IV, I, II, III
de novo stage IV or recurrent NSCLC ... at least 1 measurable lesion; Early stage (I-III) NSCLC treated with adjuvant or neoadjuvant chemotherapy then PD1/PDL1 inhibitor treatment for recurrent disease; Recurrent Unresectable stage III NSCLC treated with prior chemoradiation followed by maintenance PD1/PDL1 inhibitor with measurable disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy — metastatic
previously treated with either PD-1 / PD-L1 or the combination of PD1/PDL1 and cytotoxic chemotherapy
Must have received: anti-PD-L1 therapy — metastatic
previously treated with either PD-1 / PD-L1 or the combination of PD1/PDL1 and cytotoxic chemotherapy
Cannot have received: investigational agent
Has received investigational agents within 14 days or 5 half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
Cannot have received: monoclonal antibody
Exception: denosumab
Prior monoclonal antibody within 4 weeks before study Day 1 Exception: The use of denosumab
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate hematologic function; Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Kansas Cancer Center (KUCC) · Fairway, Kansas
- The University of Kansas Cancer Center, Westwood Campus · Kansas City, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04467723 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent, monoclonal antibody disqualifies patients from enrollment.
Are patients with EGFR alterations eligible?
No. EGFR actionable mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK actionable mutation is an exclusion criterion.
What disease stage is eligible?
Stage IV or I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages